[go: up one dir, main page]

DK1558259T3 - Ureaderivater som IL-8 -receptorantagonister - Google Patents

Ureaderivater som IL-8 -receptorantagonister

Info

Publication number
DK1558259T3
DK1558259T3 DK03781400.1T DK03781400T DK1558259T3 DK 1558259 T3 DK1558259 T3 DK 1558259T3 DK 03781400 T DK03781400 T DK 03781400T DK 1558259 T3 DK1558259 T3 DK 1558259T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
urea derivatives
urea
derivatives
antagonists
Prior art date
Application number
DK03781400.1T
Other languages
English (en)
Inventor
Jakob Busch-Petersen
Michael R Palovich
Katherine L Widdowson
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of DK1558259T3 publication Critical patent/DK1558259T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK03781400.1T 2002-10-29 2003-10-28 Ureaderivater som IL-8 -receptorantagonister DK1558259T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42195602P 2002-10-29 2002-10-29
PCT/US2003/033964 WO2004039775A2 (en) 2002-10-29 2003-10-28 Il-8 receptor antagonists

Publications (1)

Publication Number Publication Date
DK1558259T3 true DK1558259T3 (da) 2011-07-11

Family

ID=32230293

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03781400.1T DK1558259T3 (da) 2002-10-29 2003-10-28 Ureaderivater som IL-8 -receptorantagonister

Country Status (16)

Country Link
US (2) US20060040952A1 (da)
EP (2) EP2388006A1 (da)
JP (1) JP4843220B2 (da)
AR (1) AR041834A1 (da)
AT (1) ATE504300T1 (da)
AU (1) AU2003287219A1 (da)
CY (1) CY1112135T1 (da)
DE (1) DE60336672D1 (da)
DK (1) DK1558259T3 (da)
ES (1) ES2362357T3 (da)
MY (1) MY143477A (da)
PE (1) PE20040607A1 (da)
PT (1) PT1558259E (da)
SI (1) SI1558259T1 (da)
TW (1) TW200418812A (da)
WO (1) WO2004039775A2 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009039091A1 (en) * 2007-09-21 2009-03-26 Smithkline Beecham Corporation Method of treatment
JP2008517054A (ja) * 2004-10-20 2008-05-22 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
UA98456C2 (en) * 2006-04-21 2012-05-25 Смитклайн Бичам Корпорейшн Il-8 receptor antagonists
WO2007124423A2 (en) * 2006-04-21 2007-11-01 Smithkline Beecham Corporation Il-8 receptor antagonists
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
RU2017106172A (ru) * 2014-07-31 2018-08-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn)
EP3738956B1 (en) 2018-01-11 2023-03-01 Shenzhen Optimum Biological Technology Co., Ltd Cxcr2 antagonist
EP3998256A4 (en) * 2019-07-11 2023-07-19 Shenzhen Optimum Biological Technology Co., Ltd CRYSTALLINE FORM OF CXCR2 ANTAGONIST AND ITS USE

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1792156A (en) * 1928-01-17 1931-02-10 Gen Aniline Works Inc 5-halogen-2-amino-1-alkyloxy and 1-aralkyloxy-benzenes and intermediate products thereof and process of preparing them
US2363074A (en) * 1938-06-16 1944-11-21 Geigy Ag J R Halogen substituted acylamino sulphonic acids of the aromatic series and their manufacture
US2407309A (en) * 1942-02-04 1946-09-10 Squibb & Sons Inc Chemotherapeutic agents of the sulphonamide type
US2795610A (en) * 1955-03-31 1957-06-11 Du Pont Hydroxy-phenyl alkyl ureas
BE639588A (da) 1962-11-06
US3996253A (en) * 1966-01-11 1976-12-07 Minnesota Mining And Manufacturing Company Process for the preparation of color images
GB1210596A (en) 1967-04-06 1970-10-28 Armour Grocery Products Compan Antiseptic compositions
CH506240A (de) 1969-02-04 1971-04-30 Ciba Geigy Ag Verwendung von N-Hydroxyphenyl-N'-phenylharnstoffen zur Bekämpfung schädlicher Mikroorganismen ausserhalb der Textilindustrie
SE370866B (da) * 1968-03-21 1974-11-04 Ciba Geigy Ag
US3647819A (en) * 1969-09-19 1972-03-07 Sterling Drug Inc Indazolylphenylureas and indazolyl-phenylthioureas
FR2100943A1 (en) 1970-07-23 1972-03-24 Ici Ltd O-carboylcarbanilides from anthranilic acid and substd - isocyanates - immuno-suppressive agents
US4048333A (en) * 1971-08-23 1977-09-13 Medizinska Akademia Method for treating a picorna virus infection
DE2303761A1 (de) * 1973-01-26 1974-08-01 Henkel & Cie Gmbh Neue n,n'-disubstituierte thioharnstoffe, deren herstellung sowie verwendung als antimikrobielle substanzen
US4008326A (en) * 1973-12-26 1977-02-15 The Upjohn Company Substituted ureas and thioureas and pharmaceutical compositions thereof
US3932434A (en) * 1974-08-30 1976-01-13 Eli Lilly And Company N-2-(6-hydroxybenzothiazolyl)-N'-phenyl (or substituted phenyl) ureas
JPS5598152A (en) 1979-01-16 1980-07-25 Hokko Chem Ind Co Ltd Phenylurea derivative
DE2928485A1 (de) * 1979-07-14 1981-01-29 Bayer Ag Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen
GB2079480B (en) 1980-07-08 1984-05-16 Kodak Ltd Heat-activated photographic and thermal recording processes employing precursor compounds
US4608205A (en) * 1983-03-09 1986-08-26 American Cyanamid Company Polyanionic benzene ureas
US4591604A (en) * 1984-03-28 1986-05-27 American Cyanamid Company Method of inhibiting the complement system by administering multisulfonated naphthalene ureas
JPH0678298B2 (ja) 1988-03-30 1994-10-05 ワーナー‐ランバート・コンパニー Ｎ‐〔〔（２，６‐ジ置換）フエニル〕‐ｎ′‐アリールアルキル〕尿素
US5215570A (en) * 1988-10-20 1993-06-01 Ciba-Geigy Corporation Sulfamoylphenylureas
US5290814A (en) * 1988-11-21 1994-03-01 Burroughs Wellcome Co. Anti-atherosclerotic diaryl compounds
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JPH05294935A (ja) * 1991-03-15 1993-11-09 Green Cross Corp:The アミノピリジン系化合物
AU659861B2 (en) 1991-09-10 1995-06-01 Sansho Seiyaku Co., Ltd. Preparation for promoting hair growth
JP2558427B2 (ja) * 1992-06-08 1996-11-27 ゼネラル・エレクトリック・カンパニイ ポリカーボネート上にシリコーンを堆積する方法
NZ250916A (en) * 1993-02-27 1995-08-28 Nihon Nohyaku Co Ltd N-heteroaryl-n'-phenylureas, their use as acat inhibitors
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
US5312831A (en) * 1993-05-12 1994-05-17 American Cyanamid Company Urethanes and ureas that induce cytokine production
CA2123728A1 (en) * 1993-05-21 1994-11-22 Noriyoshi Sueda Urea derivatives and their use as acat inhibitors
US5401758A (en) 1993-10-07 1995-03-28 Bristol-Myers Squibb Company Pyridinyl cyanoguanidine compounds
US5547966A (en) 1993-10-07 1996-08-20 Bristol-Myers Squibb Company Aryl urea and related compounds
US5441984A (en) * 1994-01-06 1995-08-15 Eli Lilly And Company Urea, thiourea and guanidine derivatives
US5576335A (en) * 1994-02-01 1996-11-19 Nisshin Flour Milling Co., Ltd. Urea derivatives and their use as ACAT inhibitors
DE4413265A1 (de) * 1994-04-16 1995-10-19 Basf Ag Hydroxyphenylharnstoffe
EP0809492A4 (en) * 1995-02-17 2007-01-24 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
US6005008A (en) * 1996-02-16 1999-12-21 Smithkline Beecham Corporation IL-8 receptor antagonists
US6211373B1 (en) * 1996-03-20 2001-04-03 Smithkline Beecham Corporation Phenyl urea antagonists of the IL-8 receptor
US6262113B1 (en) * 1996-03-20 2001-07-17 Smithkline Beecham Corporation IL-8 receptor antagonists
BR9709938A (pt) * 1996-06-27 1999-08-10 Smithkline Beecham Corp Antagonistas dos receptores de il-8
US6218539B1 (en) * 1996-06-27 2001-04-17 Smithkline Beecham Corporation IL-8 receptor antagonists
IL127666A0 (en) * 1996-06-27 1999-10-28 Smithkline Beecham Corp IL-8 receptor antagonists
EP0907362A4 (en) 1996-06-27 1999-12-01 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
EP0915653A1 (en) 1996-06-27 1999-05-19 Smithkline Beecham Corporation Il-8 receptor antagonists
EP0934066A4 (en) * 1996-08-06 2001-10-17 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
JP2002513384A (ja) 1996-08-06 2002-05-08 スミスクライン・ビーチャム・コーポレイション Ｉｌ―８受容体アンタゴニスト
EP0957907A4 (en) * 1996-08-06 2001-08-16 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US6335352B1 (en) * 1996-08-15 2002-01-01 Smithkline Beecham Corporation IL-8 receptor antagonists
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
WO1998006398A1 (en) 1996-08-15 1998-02-19 Smithkline Beecham Corporation Il-8 receptor antagonists
EP0920253A4 (en) 1996-08-15 2001-10-17 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
EP0920417A4 (en) 1996-08-15 1999-12-29 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
US6214881B1 (en) * 1996-08-21 2001-04-10 Smithkline Beecham Corporation IL-8 receptor antagonists
US5929250A (en) * 1997-01-23 1999-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
CN1217660C (zh) * 1997-01-23 2005-09-07 史密丝克莱恩比彻姆公司 Il－8受体拮抗剂
US6436927B1 (en) * 1997-02-12 2002-08-20 Smithkline Beecham Corporation IL-8 receptor antagonists
EP1000017A4 (en) 1997-07-29 2000-10-18 Smithkline Beecham Corp ANTAGONISTS OF THE IL-8 RECEPTOR
AR015425A1 (es) * 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion
AR015426A1 (es) * 1997-09-05 2001-05-02 Smithkline Beecham Corp Compuestos de benzotiazol antagonistas del receptor de il-8, composicion farmaceutica que los contiene, su uso para la manufactura de un medicamento,procedimiento para su preparacion, compuestos intermediarios y procedimiento para su preparacion
JP2002509105A (ja) 1998-01-16 2002-03-26 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
EP1047424A4 (en) * 1998-01-20 2002-05-22 Smithkline Beecham Corp IL-8 RECEPTOR ANTAGONISTS
WO2000006557A1 (en) 1998-07-27 2000-02-10 Smithkline Beecham Corporation Novel process for making il-8 receptor antagonists
EP1107948A4 (en) 1998-08-28 2002-01-02 Smithkline Beecham IMPROVED SYNTHESIS OF 3-HYDROXY-4-AMINO-BENZONITRILE
CA2341711A1 (en) 1998-08-28 2000-03-09 Smithkline Beecham Corporation Process for making 2-amino-5-cyanophenol
HUP0103884A3 (en) * 1998-09-23 2002-11-28 Tularik Inc South San Francisc Arylsulfonanilide urea-derivatives, pharmaceutical compositions containing them and their use
UY25842A1 (es) * 1998-12-16 2001-04-30 Smithkline Beecham Corp Antagonistas de receptores de il-8
AR029637A1 (es) * 1999-05-28 2003-07-10 Smithkline Beecham Corp Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento
US20030225125A1 (en) * 1999-06-16 2003-12-04 Smithkline Beecham Corporation IL-8 receptor antagonists
US6372933B1 (en) * 1999-08-26 2002-04-16 Smithkline Beecham Corporation Process for preparing certain phenyl urea compounds
US6440993B1 (en) * 1999-10-12 2002-08-27 Smithkline Beecham Corporation IL-8 receptor antagonists
AU2001241896A1 (en) * 2000-03-01 2001-09-12 Smith Kline Beecham Corporation Il-8 receptor antagonists
US20030050298A1 (en) * 2000-03-10 2003-03-13 Palovich Michael R Il-8 receptor antagonists
MY133845A (en) * 2000-03-10 2007-11-30 Smithkline Beecham Corp Il-8 receptor antagonists
US6767922B2 (en) * 2000-03-14 2004-07-27 Smithkline Beecham Corporation IL-8 receptor antagonists
US6664259B2 (en) * 2000-03-16 2003-12-16 Smithkline Beecham Corporation Il-8 receptor antagonists
UY26627A1 (es) * 2000-03-24 2001-09-28 Smithkline Beecham Corp Antagonistas de receptores de il-8
JP2003530328A (ja) * 2000-04-07 2003-10-14 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
US6432960B2 (en) * 2000-05-10 2002-08-13 Bristol-Myers Squibb Company Squarate derivatives of dihydropyridine NPY antagonists
EP1284956A4 (en) * 2000-05-30 2005-08-24 Smithkline Beecham Corp ANTAGONISTS OF THE IL-8 RECEPTOR
US20040048897A1 (en) * 2001-01-16 2004-03-11 Mccleland Brent Il-8 receptor antagonists
US20040132694A1 (en) * 2001-01-16 2004-07-08 Palovich Michael R. Il-8 receptor antagonists
RU2003126913A (ru) * 2001-02-02 2005-03-10 Шеринг Корпорейшн (US) 3,4-дизамещенные циклобутен-1,2-дионы, как антагонисты хемокинового рецептора схс
US20030204085A1 (en) * 2001-02-02 2003-10-30 Taveras Arthur G. 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists
KR20030088044A (ko) * 2001-03-30 2003-11-15 스미스클라인 비참 코포레이션 페놀-함유 화합물의 합성 방법
ATE338035T1 (de) * 2001-06-05 2006-09-15 Boehringer Ingelheim Pharma 1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen
US20040038854A1 (en) * 2001-07-16 2004-02-26 Dillon Susan B. Use of il-8 receptor antagonists in the treatment of virus infections
US20030032802A1 (en) * 2002-08-30 2003-02-13 Palovich Michael R. IL8-receptor antagonists
US20030028042A1 (en) * 2002-08-30 2003-02-06 Palovich Michael R. Il8-receptor antagonists
US20030065170A1 (en) * 2002-09-05 2003-04-03 Widdowson Katherine Louisa Il-8 receptor antagonists
EP1631559A4 (en) * 2003-06-06 2008-08-27 Smithkline Beecham Corp IL-8 SB / SB RECEPTOR ANTAGONISTS
JP2008517054A (ja) * 2004-10-20 2008-05-22 スミスクライン・ビーチャム・コーポレイション Ｉｌ−８受容体アンタゴニスト
UA98456C2 (en) * 2006-04-21 2012-05-25 Смитклайн Бичам Корпорейшн Il-8 receptor antagonists
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
WO2008070707A1 (en) 2006-12-05 2008-06-12 Smithkline Beecham Corporation Il-8 receptor antagonists

Also Published As

Publication number Publication date
CY1112135T1 (el) 2015-11-04
JP2006506404A (ja) 2006-02-23
US7709485B2 (en) 2010-05-04
US20060040952A1 (en) 2006-02-23
ATE504300T1 (de) 2011-04-15
EP2388006A1 (en) 2011-11-23
DE60336672D1 (de) 2011-05-19
ES2362357T3 (es) 2011-07-04
EP1558259A4 (en) 2009-04-08
WO2004039775A2 (en) 2004-05-13
AU2003287219A8 (en) 2004-05-25
TW200418812A (en) 2004-10-01
WO2004039775A3 (en) 2004-08-26
PE20040607A1 (es) 2004-09-18
AR041834A1 (es) 2005-06-01
JP4843220B2 (ja) 2011-12-21
SI1558259T1 (sl) 2011-06-30
PT1558259E (pt) 2011-06-17
EP1558259A2 (en) 2005-08-03
AU2003287219A1 (en) 2004-05-25
US20090093492A1 (en) 2009-04-09
EP1558259B1 (en) 2011-04-06
MY143477A (en) 2011-05-31

Similar Documents

Publication Publication Date Title
DK1562595T3 (da) Diarylethere som opioidreceptorantagonister
CY2017032I2 (el) Παραγωγα (θειο)καρβαμοϋλ-κυκλοεξανιου ως ανταγωνιστες των υποδοχεων d3/d2
DK1501809T3 (da) Trizolderivater som tachykininreceptorantagonister
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1383750T3 (da) Urinstofderivater som integrin a4 antagonister
DK1499316T3 (da) (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister
NO20012948L (no) Hydroksydifenylureasulfonamider som IL-8 reseptor antagonister
DK1638969T3 (da) CGRP-receptorantagonister
IS7667A (is) Nýjar bensimídazólafleiður
NO20040028L (no) Substituerte anilinske piperidiner som MCH-selektive antagonister
NO20055238D0 (no) Kondenserte N-heterocykliske forbindelser og deres anvendelse som CRF-reseptorantagonister
DK1349839T3 (da) Phenylethenyl- eller phenylethinylderivater som glutamatraceptorantagonister
ATE346043T1 (de) Il-8-rezeptorantagonisten
NO20052797D0 (no) Fenyl eller heteroaryl aminoalkanderivater som IP-reseptorantagonister
DK1761519T3 (da) Indolderivater som histaminreceptorantagonister
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
DK1833791T3 (da) 2,3,4,9-tetrahydor-1H-carbazolderivater som CRTH2 receptorantagonister
DK1636206T3 (da) Imidazolderivater som glutamatreceptorantagonister
NO20044373L (no) Azetidinderivater som CCR-3-reseptorantagonister
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE492535T1 (de) 4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren
DK1558259T3 (da) Ureaderivater som IL-8 -receptorantagonister
NO20043799L (no) 2-oksasolaminer og deres anvendelse som 5-HT2B reseptor antagonister
NO20055758D0 (no) Heteroarylsubstituerte imidazolderivater som glutamatreseptorantagonister